Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience Clinical article

被引:36
|
作者
Van Poppel, Mark [2 ]
Klimo, Paul, Jr. [2 ]
Dewire, Mariko [1 ]
Sanford, Robert A. [2 ]
Boop, Frederick [2 ]
Broniscer, Alberto [1 ]
Wright, Karen [1 ]
Gajjar, Amar J. [1 ]
机构
[1] St Jude Childrens Hosp, Div Neurooncol, Dept Oncol, Memphis, TN 38105 USA
[2] Univ Tennessee, Coll Med, Div Pediat Neurosurg, Memphis, TN USA
关键词
neoadjuvant chemotherapy; pediatric brain tumor; infant; blood loss; surgery; oncology; CHOROID-PLEXUS CARCINOMA; PREOPERATIVE CHEMOTHERAPY; YOUNG-CHILDREN; POSTOPERATIVE CHEMOTHERAPY; SURGICAL RESECTION; CHILDHOOD-CANCER; MEDULLOBLASTOMA; CARBOPLATIN; RADIATION;
D O I
10.3171/2011.6.PEDS11158
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Brain tumors in infants are often large, high grade, and vascular, making complete resection difficult and placing children at risk for neurological complications and excessive blood loss. Neoadjuvant chemotherapy may reduce tumor vascularity and volume, which can facilitate resection. The authors evaluated how an ongoing institutional prospective chemotherapy trial would affect patients who did not have a gross-total resection (GTR) immediately and who therefore required further surgical intervention to achieve definitive tumor resection. Methods. Thirteen infants (4 girls and 9 boys) who were enrolled in an institutional protocol in which they were treated with multiagent chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide with vinblastine for high-risk patients) subsequently underwent second-look surgery. The primary outcome was extent of resection achieved in postchemotherapy surgery. Secondary outcomes included intraoperative blood loss, radiographic response to the chemotherapy, complications during chemotherapy, and survival. Results. Three infants underwent biopsy, 9 underwent subtotal resection, and 1 patient did not undergo surgery prior to chemotherapy. On subsequent second-look surgery, 11 of 13 patients had a GTR, I had a near-total resection, and I had a subtotal resection. In each case, a marked reduction in tumor vascularity was observed intraoperatively. The average blood loss was 19% of estimated blood volume, and 6(46%) of 13 patients required a blood transfusion. Radiographically, chemotherapy induced a reduction in tumor volume in 9(69%) of 13 patients. Emergency surgery was required in 2 patients during chemotherapy, 1 for intratumoral hemorrhage and 1 for worsening peritumoral edema. The average follow-up period for this cohort was 16.5 months, and at last follow-up, 4 patients (31%) had died, 1 patient had progressive metastatic spinal disease, and the rest had either no evidence of disease or stable disease. Conclusions. A GTR of pediatric brain tumors is one of the most important predictors of outcome. The application of the authors' neoadjuvant induction chemotherapy protocol in a variety of tumor types resulted in devascularization of all tumors and volume regression in the majority, and subsequently facilitated resection, with acceptable intraoperative blood loss. Intracranial complications may occur during chemotherapy, ranging from incidental and asymptomatic to life threatening, necessitating close monitoring of these children. (DOI: 10.3171/2011.6.PEDS11158)
引用
收藏
页码:251 / 256
页数:6
相关论文
共 50 条
  • [1] NEOADJUVANT CHEMOTHERAPY FOR INFANTILE BRAIN TUMORS
    Ogiwara, Hideki
    Kiyotani, Chikako
    Terashima, Keita
    Morota, Nobuhito
    NEURO-ONCOLOGY, 2014, 16 : 105 - 105
  • [2] Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital
    Fernandez-Pineda, Israel
    Spunt, Sheri L.
    Parida, Lalit
    Krasin, Matthew J.
    Davidoff, Andrew M.
    Rao, Bhaskar N.
    JOURNAL OF PEDIATRIC SURGERY, 2011, 46 (11) : 2071 - 2075
  • [3] Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource
    Kyle S. Smith
    Ke Xu
    Kimberly S. Mercer
    Frederick Boop
    Paul Klimo
    Michael DeCupyere
    Jose Grenet
    Sarah Robinson
    Paige Dunphy
    Suzanne J. Baker
    David W. Ellison
    Thomas E. Merchant
    Santhosh A. Upadayaya
    Amar Gajjar
    Gang Wu
    Brent A. Orr
    Giles W. Robinson
    Paul A. Northcott
    Martine F. Roussel
    Acta Neuropathologica, 2020, 140 : 209 - 225
  • [4] Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource
    Smith, Kyle S.
    Xu, Ke
    Mercer, Kimberly S.
    Boop, Frederick
    Klimo, Paul
    DeCupyere, Michael
    Grenet, Jose
    Robinson, Sarah
    Dunphy, Paige
    Baker, Suzanne J.
    Ellison, David W.
    Merchant, Thomas E.
    Upadayaya, Santhosh A.
    Gajjar, Amar
    Wu, Gang
    Orr, Brent A.
    Robinson, Giles W.
    Northcott, Paul A.
    Roussel, Martine F.
    ACTA NEUROPATHOLOGICA, 2020, 140 (02) : 209 - 225
  • [5] Survival after recurrence of Ewing tumors - The St. Jude Children's Research Hospital experience, 1979-1999
    Rodriguez-Galindo, C
    Billups, CA
    Kun, LE
    Rao, BN
    Pratt, CB
    Merchant, TE
    Santana, VM
    Pappo, AS
    CANCER, 2002, 94 (02) : 561 - 569
  • [6] Outcome after relapse of childhood acute myeloid leukemia: The St. Jude experience.
    Rubnitz, J
    Razzouk, B
    Lensing, S
    Pounds, S
    Pui, CH
    Ribeiro, R
    BLOOD, 2005, 106 (11) : 83A - 84A
  • [7] Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience
    Klimo, Paul, Jr.
    Panandiker, Atmaram S. Pai
    Thompson, Clinton J.
    Boop, Frederick A.
    Qaddoumi, Ibrahim
    Gajjar, Amar
    Armstrong, Gregory T.
    Ellison, David W.
    Kun, Larry E.
    Ogg, Robert J.
    Sanford, Robert A.
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2013, 11 (03) : 274 - 281
  • [8] Extraction of St. Jude Riata Leads: Clinical Experience and Outcomes at a High Volume Extraction Center
    Sager, Solomon J.
    Carrillo, Roger G.
    CIRCULATION, 2012, 126 (21)
  • [9] Laparoscopic Resection After Neoadjuvant Chemotherapy for Distal Gastric Tumors Safe, but Is It Better?
    Sachs, Teviah E.
    Tseng, Jennifer F.
    JAMA SURGERY, 2019, 154 (12) : 1101 - 1102
  • [10] Oxford experience with neoadjuvant chemotherapy and surgical resection for esophageal adenocarcinomas and squamous cell tumors
    Safranek, P. M.
    Sujendran, V.
    Baron, R.
    Warner, N.
    Blesing, C.
    Maynard, N. D.
    DISEASES OF THE ESOPHAGUS, 2008, 21 (03) : 201 - 206